ArticleJournal for immunotherapy of cancer2025

Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade.

David N Ciccone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.